Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 5/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.47 |
| ▸ | CCNK | O75909 | 1/20 | 0.46 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10135662 | 0.96 | TBK1 (0.48) | GPR119MEN1KMT2ATBK1IDO1 | |
| SCHEMBL10135594 | 0.96 | GPR119 (0.47) | GPR119MEN1KMT2ATBK1IDO1 | |
| SCHEMBL17276352 | 0.85 | FAAH (0.58) | MEN1KMT2A | |
| SCHEMBL16855862 | 0.85 | FAAH (0.58) | MEN1KMT2A | |
| SCHEMBL10135645 | 0.85 | GPR119 (0.47) | GPR119NAMPT | |
| SCHEMBL10135796 | 0.85 | GPR119 (0.49) | GPR119TBK1NAMPT | |
| SCHEMBL10135625 | 0.83 | GPR119 (0.50) | GPR119TBK1NAMPT | |
| SCHEMBL10135761 | 0.83 | GPR119 (0.46) | GPR119NAMPT | |
| SCHEMBL1088443 | 0.82 | GPR119 (0.59) | GPR119MEN1KMT2A | |
| SCHEMBL18024152 | 0.82 | IDO1 (0.49) | GPR119TBK1IDO1TDO2IDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT1A1, SULT1E1, SULT2A1 | GPR119 2496/4885MEN1 3295/4885KMT2A 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.